Phenylpropylaminopentane
Sign in to save1-Phenyl-2-propylaminopentane (PPAP), also known as 'α,N-dipropylphenethylamine (DPPEA) and by the developmental code name MK-306', is an experimental drug related to selegiline which acts as a catecholaminergic activity enhancer (CAE).
~8 min read
Encyclopedic overview
14 sectionsContents
- Pharmacology
- Pharmacodynamics
- Catecholaminergic activity enhancer
- Catecholamine reuptake inhibitor
- Other actions
- Chemistry
- History
- Society and culture
- Legal status
- Sweden
- Research
- See also
- References
- External links
1-Phenyl-2-propylaminopentane (PPAP), also known as 'α,N-dipropylphenethylamine (DPPEA) and by the developmental code name MK-306', is an experimental drug related to selegiline which acts as a catecholaminergic activity enhancer (CAE).
PPAP is a CAE and enhances the nerve impulse propagation-mediated release of norepinephrine and dopamine. It produces psychostimulant-like effects in animals. In 2025, it was discovered that PPAP is a potent catecholamine reuptake inhibitor, including of dopamine and to a lesser extent of norepinephrine. The drug is a phenethylamine and amphetamine derivative and was derived via structural modification of selegiline.
Excerpted from Wikipedia’s “Phenylpropylaminopentane” article, available under the CC BY-SA 4.0 licence.